MARKET

ZTS

ZTS

Zoetis
NYSE

Real-time Quotes | Nasdaq Last Sale

222.97
-0.36
-0.16%
After Hours: 222.97 0 0.00% 16:12 12/06 EST
OPEN
222.90
PREV CLOSE
223.33
HIGH
224.96
LOW
220.99
VOLUME
1.21M
TURNOVER
--
52 WEEK HIGH
228.89
52 WEEK LOW
141.41
MARKET CAP
105.49B
P/E (TTM)
53.70
1D
5D
1M
3M
1Y
5Y
Zoetis Named One of Newsweek’s Most Responsible Companies for 2022
Zoetis has been named to Newsweek Magazine's America's Most Responsible Companies 2022 list , which recognizes top-performing companies that are making a difference through their environmental, social and corporate governance actions. The company...
Business Wire · 4d ago
Here's How Much You Would Have Made Owning Zoetis Stock In The Last 5 Years
Zoetis (NYSE:ZTS) has outperformed the market over the past 5 years by 19.02% on an annualized basis.
Benzinga · 4d ago
Is Biofrontera a Good Pharmaceuticals Stock to Own?
StockNews.com · 4d ago
4 Dependable Healthcare Stocks to Buy Hand Over Fist Right Now
StockNews.com · 5d ago
Nicolai Tangen’s AKO Capital Is Investing In These 10 Stocks
In this article, we discuss 10 stocks Nicolai Tangen’s AKO Capital is investing in. If you want to skip our detailed analysis of Tangen’s history, investment philosophy, and hedge fund performance, go directly to Nicolai Tangen’s AKO Capital Is Investing I...
Insider Monkey · 6d ago
Zoetis Inc (ZTS) CEO Kristin C Peck Sold $3.2 million of Shares
GuruFocus News · 11/29 20:15
4 Large-Cap Stocks With High Returns on Equity
GuruFocus News · 11/28 13:39
Zoetis (NYSE:ZTS) jumps 4.4% this week, though earnings growth is still tracking behind five-year shareholder returns
Buying shares in the best businesses can build meaningful wealth for you and your family. And highest quality companies...
Simply Wall St. · 11/22 18:29
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ZTS. Analyze the recent business situations of Zoetis through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 17 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

35.29%Strong Buy
52.94%Buy
11.76%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average ZTS stock price target is 238.83 with a high estimate of 264.00 and a low estimate of 184.00.
High264.00
Average238.83
Low184.00
Current 222.97
EPS
Actual
Estimate
0.320.630.941.26
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 1.81K
Institutional Holdings: 466.44M
% Owned: 98.59%
Shares Outstanding: 473.13M
TypeInstitutionsShares
Increased
564
17.62M
New
107
2.20M
Decreased
528
17.14M
Sold Out
68
889.75K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.40%
Pharmaceuticals & Medical Research
-0.64%
Key Executives
Non-Executive Chairman/Independent Director
Michael Mccallister
Chief Executive Officer/Director
Kristin Peck
Chief Financial Officer/Executive Vice President
Wetteny Joseph
Chief Human Resource Officer/Executive Vice President
Roxanne Lagano
Executive Vice President/Chief Information Officer
Wafaa Mamilli
Executive Vice President/General Counsel/Secretary
Heidi Chen
Executive Vice President
Timothy Bettington
Executive Vice President
Robert Kelly
Executive Vice President
Catherine Knupp
Executive Vice President
J. Michael McFarland
Executive Vice President
Abhay Nayak
Executive Vice President
Sherry Pudloski
Executive Vice President
Roman Trawicki
Independent Director
Paul Bisaro
Independent Director
Frank D'amelio
Independent Director
Sanjay Khosla
Independent Director
Antoinette Leatherberry
Independent Director
Gregory Norden
Independent Director
Louise Parent
Independent Director
Willie Reed
Independent Director
Linda Rhodes
Independent Director
Robert Scully
Declaration Date
Dividend Per Share
Ex-Div Date
10/14/2021
Dividend USD 0.25
10/28/2021
05/20/2021
Dividend USD 0.25
07/20/2021
02/10/2021
Dividend USD 0.25
04/20/2021
12/09/2020
Dividend USD 0.25
01/19/2021
10/07/2020
Dividend USD 0.2
10/20/2020
05/20/2020
Dividend USD 0.2
07/16/2020
02/11/2020
Dividend USD 0.2
04/16/2020
12/11/2019
Dividend USD 0.2
01/16/2020
10/03/2019
Dividend USD 0.164
10/21/2019
05/15/2019
Dividend USD 0.164
07/18/2019
02/12/2019
Dividend USD 0.164
04/17/2019
12/12/2018
Dividend USD 0.164
01/17/2019
10/10/2018
Dividend USD 0.126
11/19/2018
05/15/2018
Dividend USD 0.126
07/19/2018
02/13/2018
Dividend USD 0.126
04/19/2018
12/11/2017
Dividend USD 0.126
01/18/2018
10/05/2017
Dividend USD 0.105
11/08/2017
05/22/2017
Dividend USD 0.105
06/13/2017
02/15/2017
Dividend USD 0.105
04/04/2017
12/07/2016
Dividend USD 0.105
01/18/2017
About ZTS
Zoetis Inc. is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products, biodevices, genetic tests and precision livestock farming technology. The Company has a business, commercializing products across eight core species: dogs, cats and horses (collectively, companion animals) and cattle, swine, poultry, fish and sheep (collectively, livestock); and within product categories such as vaccines, anti-infectives, parasiticides, dermatology, other pharmaceutical products, medicated feed additives and animal health diagnostics. The Company's segments include the United States and International. Within each of these operating segments, it offers a product portfolio for both livestock and companion animal customers.

Webull offers kinds of Zoetis Inc stock information, including NYSE:ZTS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ZTS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ZTS stock methods without spending real money on the virtual paper trading platform.